TearLab Corp fka TEAR

[stockmule]

This part of the transcript was the most interesting. Were they not knowledgeable on how to submit the findings or just don't have the results.
Could be a great buying opportunity.


We understand the FDA’s position and are encouraged by the clear guidance they have provided. We are working diligently to compile the additional information necessary to achieve a 510(k) clearance,” said Seph Jensen, TearLab’s Chief Executive Officer. “We maintain o ur belief that TearLab Discovery represents a breakthrough technology capable of providing clinically efficient, cost-effective, point-of-care diagnostic tests. We will continue working with the FDA to provide additional data for a new MMP-9 submission and remain committed to securing its 510(k) clearance.”